timothy sykes logo
REPL Stock Collapses As FDA Rejects RP1 Melanoma Bid Thumbnail
G Google News

REPL Stock Collapses As FDA Rejects RP1 Melanoma Bid

BRYCE TUOHEY•UPDATED APR. 25, 2026, 10:05 AM ET
Reviewed by Tim Sykesand Fact-checked by Matt Monaco

Replimune Group Inc. stocks have been trading down by -15.79 percent following bearish sentiment around its latest clinical trial update.

Candlestick Chart

Weekly Update Apr 20 – Apr 24, 2026: On Saturday, April 25, 2026 Replimune Group Inc. stock [NASDAQ: REPL] is trending down by -15.79%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Healthcare industry expert:

Analyst sentiment – negative

Replimune is now a distressed small-cap oncology developer with a roughly $7M enterprise value, reflecting investor capitulation after the RP1 BLA failure. Fundamentals are weak: FY Q3 net income was -$71M (EPS -$0.77) with EBITDA -$67.6M and operating cash flow -$66.0M, implying an annualized burn rate that will erode the $269M cash and investments base within several years. Returns on capital are deeply negative (ROE LTM -90.9%, ROA LTM -67.2%), yet liquidity remains strong (current ratio 5.6, quick ratio 5.4, debt/equity 0.36), giving management time but little value credit for the pipeline.

Technically, the stock is in a short-term rebound within a dominant downtrend following a high-volume collapse. Over the last five sessions, price has bounced from 1.83 to a 2.85 intraday high before settling at 2.40, signaling aggressive dip-buying but also overhead supply. Five-minute candles show fading momentum near 2.80–2.90 with volume spikes, defining that band as near-term resistance. The key actionable level is support at 1.80–1.90; below 1.80, downside air pocket likely triggers stop-driven selling.

Catalysts are overwhelmingly negative: a second FDA Complete Response Letter for RP1 in PD-1–refractory melanoma effectively removes the lead value driver, prompting across-the-board downgrades to Hold/Neutral or worse and price targets cut to $2–$4, well below prior expectations and sector medians. Legal overhang from securities investigations further depresses sentiment. Versus Healthcare and Biotech benchmarks, REPL now trades as an asset-value, optionality play. My verdict is Negative, with resistance at $2.80–3.00 and downside risk toward $1.25 absent a credible new pipeline strategy.

Quick Financial Overview

Replimune Group Inc. (REPL) is trading like a broken biotech story after the RP1 melanoma failure. Weekly prices show a sharp rebound attempt from the low $2 area: the stock opened near $2.09, dipped to $1.83, then bounced as high as $2.88 before fading back to around $2.40. That pattern tells traders there is aggressive dip-buying, but also fast profit-taking, typical of a name now driven by speculation rather than steady conviction. Intraday, a 5‑minute candle with a $2.78 high and a $2.37 low, closing at $2.42, confirms active day-trading and wide ranges.

On the fundamentals, Replimune Group Inc. is a classic clinical-stage biotech profile: heavy losses, no clear profitability, and a balance sheet that matters more than earnings. The latest quarterly income statement shows net income of about -$70.9M and EBITDA of roughly -$67.6M, driven mainly by $53.1M in research expense and $18.7M in general and administrative costs. With basic and diluted EPS at about -$0.77 on roughly 92.2M average shares, the company is burning significant cash to support its pipeline.

More Breaking News

Cash and liquidity are key after RP1’s setback. The balance sheet lists about $122.9M in cash and $269.1M when you include cash, cash equivalents, and short-term investments, against total liabilities of about $123.1M. Working capital sits near $230.3M, helped by a strong current ratio of 5.6 and quick ratio of 5.4, which buys time but not a long-term solution if losses stay at current levels. Cash flow from operations was roughly -$65.9M in the latest period, with free cash flow about -$66.1M, meaning REPL may eventually need to cut spend, raise capital, or both if new assets do not step up quickly.

Conclusion

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

Click Here for a Millionaire's POV on Trading REPL

Millionaire's
POV on REPL

Don't miss the next
big breakout.

GET POV
Tim Sykes

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”